var data={"title":"Mycophenolate mofetil (Cellcept) and enteric-coated mycophenolate sodium (Myfortic): Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Mycophenolate mofetil (Cellcept) and enteric-coated mycophenolate sodium (Myfortic): Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6612?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=mycophenolate-mofetil-cellcept-and-enteric-coated-mycophenolate-sodium-myfortic-drug-information\" class=\"drug drug_general\">see &quot;Mycophenolate mofetil (Cellcept) and enteric-coated mycophenolate sodium (Myfortic): Drug information&quot;</a> and <a href=\"topic.htm?path=mycophenolate-mofetil-cellcept-and-enteric-coated-mycophenolate-sodium-myfortic-patient-drug-information\" class=\"drug drug_patient\">see &quot;Mycophenolate mofetil (Cellcept) and enteric-coated mycophenolate sodium (Myfortic): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5709159\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Experienced physician:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Only health care providers experienced in immunosuppressive therapy and management of organ transplant patients should prescribe mycophenolate. Manage patients receiving the drug in facilities equipped and staffed with adequate laboratory and supportive medical resources. The health care provider responsible for maintenance therapy should have complete information requisite for the follow-up of the patient.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Serious infections: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Immunosuppression may lead to increased susceptibility to bacterial, viral, fungal, and protozoal infections, including opportunistic infections. </p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Malignancies and serious infections:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-4em;margin-left:4em;\">Immunosuppression may lead to increased risk of development of lymphoma and other malignancies, particularly of the skin. </p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Embryo-fetal toxicity:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Use during pregnancy is associated with increased risks of first trimester pregnancy loss and congenital malformations. Women of reproductive potential must be counseled regarding pregnancy prevention and planning.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F198686\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>CellCept;</li>\n      <li>CellCept Intravenous;</li>\n      <li>Myfortic</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F198687\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>CellCept;</li>\n      <li>CellCept I.V.;</li>\n      <li>Myfortic</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1048786\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Immunosuppressant Agent</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1048778\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=mycophenolate-mofetil-cellcept-and-enteric-coated-mycophenolate-sodium-myfortic-drug-information\" class=\"drug drug_general\">see &quot;Mycophenolate mofetil (Cellcept) and enteric-coated mycophenolate sodium (Myfortic): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> May be used IV for up to 14 days; transition to oral therapy as soon as tolerated. Mycophenolate mofetil (CellCept) tablets, capsules, and suspension should not be interchanged with the delayed release tablet formulation (Myfortic) due to differences in the rate of absorption.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Renal transplantation: </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Mycophenolate mofetil (CellCept):</i> Infants &ge;3 months, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Suspension: 600 mg/m<sup>2</sup>/dose twice daily; maximum daily dose: 2000 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Tablets or capsules: </p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">BSA 1.25 m<sup>2</sup> to 1.5 m<sup>2</sup>: 750 mg twice daily </p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">BSA &gt;1.5 m<sup>2</sup>: 1000 mg twice daily </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Mycophenolate sodium delayed release tablets (Myfortic):</i> Children &ge;5 years and Adolescents: 400 mg/m<sup>2</sup>/dose twice daily; maximum daily dose: 1440 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Alternate fixed dosing:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">BSA &lt;1.19 m<sup>2</sup>: Use of this formulation is not recommended </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">BSA 1.19 to 1.58 m<sup>2</sup>: 540 mg twice daily </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">BSA &gt;1.58 m<sup>2</sup>: 720 mg twice daily </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <b>Note:</b> Mycophenolate sodium delayed release 720 mg twice daily was shown to be bioequivalent to mycophenolate mofetil 1000 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Lupus nephritis:</b> Limited data available: Mycophenolate mofetil (CellCept): Children and Adolescents: Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">BSA-based dosing:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Induction: 300-600 mg/m<sup>2</sup>/dose twice daily; maximum daily dose: 3000 mg/<b>day</b> (Aragon, 2010; Hobbs, 2010; Marks, 2010; Wong, 2009) </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Maintenance: Initial: 300-600 mg/m<sup>2</sup>/dose twice daily; reported maximum daily dose range: 2000-3000 mg/<b>day</b> (Baskin, 2010; Cramer, 2007; Marks, 2010); once disease stabilized and remission maintained may consider dosage reduction.  </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Fixed dosing: Children &ge;5 years and Adolescents: Induction or maintenance: Initial: 250-500 mg twice daily and gradually increased up to 750-1000 mg twice daily; doses based on small retrospective studies (n=52); doses equivalent to 10-12.5 mg/kg/dose twice daily (Appel, 2009; Falcini, 2009; Kazyra, 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Nephrotic syndrome:</b> Limited data available: Mycophenolate mofetil (CellCept): Children and Adolescents: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Frequently relapsing:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\"> BSA-based dosing: 600 mg/m<sup>2</sup>/dose twice daily for at least 12 months; maximum daily dose: 2000 mg/<b>day</b> (Beck, 2013; Gipson, 2009; KDIGO, 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Weight-based dosing: 12.5-18 mg/kg/dose twice daily; maximum daily dose: 2000 mg/<b>day</b> for 1-2 years with a tapering dose of prednisone (Gipson, 2009) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Steroid-dependent (for steroid sparing effect): </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">BSA-based dosing: 600 mg/m<sup>2</sup>/dose twice daily for at least 12 months; maximum daily dose: 2000 mg/<b>day</b> (Gipson, 2009; KDIGO, 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Weight-based dosing: 12-18 mg/kg/dose twice daily; maximum daily dose: 2000 mg/<b>day</b> (Gipson, 2009) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Note:</b> May be used IV for up to 14 days; transition to oral therapy as soon as tolerated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Renal transplantation: </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>CellCept:</i> IV, Oral: 1000 mg twice daily. Doses &gt;2000 mg daily are not recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Myfortic:</i> Oral: 720 mg twice daily </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Cardiac transplantation:</b> <i>CellCept:</i> IV, Oral: 1500 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hepatic transplantation:</b> <i>CellCept:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: 1500 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: 1000 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Lupus nephritis:</b> <i>CellCept:</i> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Induction: 1000 mg twice daily for 6 months in combination with a glucocorticoid (Ong, 2005) <b>or</b> 2000-3000 mg daily for 6 months in combination with glucocorticoids (Hahn, 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Maintenance: 500-3000 mg daily (Contreras, 2004) <b>or</b> 1000 mg twice daily (Dooley, 2011) <b>or</b> 1000-2000 mg daily (Hahn, 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants, Children, and Adolescents: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Mycophenolate mofetil (CellCept): Infants &ge;3 months, Children, and Adolescents: Patients should be carefully observed; no dose adjustments are needed in renal transplant patients experiencing delayed graft function postoperatively. Avoid doses &gt;1 g twice daily. </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Mycophenolate delayed release tablet (Myfortic): Children &ge;5 years and Adolescents: No dose adjustments are needed in renal transplant patients experiencing delayed graft function postoperatively; however, monitor carefully for potential concentration dependent adverse events.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Renal transplant:</b> GFR &lt;25 mL/minute/1.73 m<sup>2</sup> outside the immediate post-transplant period: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Mycophenolate mofetil (CellCept): Avoid doses &gt;1 g twice daily; patients should also be carefully observed; no dose adjustments are needed in renal transplant patients experiencing delayed graft function postoperatively  </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Mycophenolate delayed release tablet (Myfortic): No dose adjustments are needed in renal transplant patients experiencing delayed graft function postoperatively; however, monitor carefully for potential concentration dependent adverse events.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Cardiac or liver transplant:</b> No data available; mycophenolate may be used in cardiac or hepatic transplant patients with severe chronic renal impairment if the potential benefit outweighs the potential risk.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Hemodialysis:</b> Not removed; supplemental dose is not necessary. </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Peritoneal dialysis</b>: Supplemental dose is not necessary</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> Infants &ge;3 months, Children, Adolescents, and Adults: No dosage adjustment is recommended for renal patients with severe hepatic parenchymal disease; however, it is not currently known whether dosage adjustments are necessary for hepatic disease with other etiologies.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment for toxicity (neutropenia):</b> ANC &lt;1.3 x 103/&mu;L or anemia; Dosing should be interrupted or the dose reduced </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F198659\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral, as mofetil: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CellCept: 250 mg [contains fd&amp;c blue #2 (indigotine)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 250 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous, as mofetil hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CellCept Intravenous: 500 mg (1 ea) [contains polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 500 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension Reconstituted, Oral, as mofetil: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CellCept: 200 mg/mL (160 mL) [contains aspartame, methylparaben, sorbitol, soybean lecithin; mixed fruit flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 200 mg/mL (160 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral, as mofetil: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CellCept: 500 mg [contains fd&amp;c blue #2 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 500 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Delayed Release, Oral, as mycophenolic acid: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Myfortic: 180 mg [contains fd&amp;c blue #2 (indigotine)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Myfortic: 360 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 180 mg, 360 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F198644\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7874743\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Myfortic: <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM172735.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/+nIf162NgDrXSMpjxmnBPQaIxh8Hco9F8HyORMH6RfMg==&amp;TOPIC_ID=12624\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM172735.pdf</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CellCept: <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM170919.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/+nIf162NgDrXSMpjxmnBPQ0AIED7JFY5eSqJp8L4eB4w==&amp;TOPIC_ID=12624\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM170919.pdf</a></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1048789\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Oral (capsule, tablet, suspension): Administer on an empty stomach 1 hour before or 2 hours after food to avoid variability in absorption; CellCept may be administered with food in stable renal transplant patients when necessary. Shake suspension well before use; may be administered via a nasogastric tube (minimum: 8 French, 1.7 mm interior diameter); oral suspension should not be mixed with other medications. Delayed release tablets should be swallowed whole; do not crush, chew, or cut. If a dose is missed, administer as soon as it is remembered. If it is close to the next scheduled dose, skip the missed dose and resume at next regularly scheduled time; do not double a dose to make up for a missed dose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">IV: <b>Do not administer IV push</b> or by rapid IV bolus injection; administer by slow IV infusion over a period of no less than 2 hours. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49132818\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 2]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends single gloving for administration of intact tablets or capsules. If manipulating tablets/capsules (eg, to prepare an oral suspension), NIOSH recommends double gloving, a protective gown, and preparation in a controlled device; if not prepared in a controlled device, respiratory and eye/face protection as well as ventilated engineering controls are recommended. NIOSH recommends double gloving, a protective gown, and (if there is a potential for vomit or spit up) eye/face protection for administration of an oral liquid/feeding tube administration. For IV preparation, NIOSH recommends double gloving, a protective gown, ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator), and closed system transfer devices (CSTDs) when compounding. Double gloving and a gown are required during IV administration (NIOSH 2016). Assess risk to determine appropriate containment strategy (USP-NF 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F198680\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsules: Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablets: Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Protect from moisture and light. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Oral suspension: Store powder for oral suspension at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Once reconstituted, the oral solution may be stored at room temperature or under refrigeration. Do not freeze. The mixed suspension is stable for 60 days. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Injection: Store intact vials and solutions diluted in D5W at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Begin infusion within 4 hours of reconstitution. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1048788\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Immunosuppressant agent used in conjunction with other immunosuppressive therapies (eg, cyclosporine and corticosteroids with or without antithymocyte induction) for the prophylaxis of organ rejection in patients receiving allogeneic renal (CellCept: FDA approved in ages &ge;3 months and adults; Myfortic: FDA approved in ages &ge;5 years who are at least 6 months post-transplant and adults), hepatic, or cardiac transplants (CellCept: FDA approved in adults). Has also been used in nephrotic syndrome; intestine, small bowel, and bone marrow transplant patients; moderate to severe psoriasis; chronic graft-versus-host disease; myasthenia gravis; lupus nephritis; autoimmune lymphoproliferative syndrome juvenile localized scleroderma, uveitis and refractory immune thrombocytopenia (ITP).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: Immunosuppressant agent used in conjunction with other immunosuppressive therapies (eg, cyclosporine and corticosteroids with or without antithymocyte induction) for the prophylaxis of organ rejection in patients receiving allogeneic renal, hepatic, or cardiac transplants (CellCept: FDA approved in adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25708052\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes that have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F198716\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">In general, lower doses used in renal rejection patients had less adverse effects than higher doses. Rates of adverse effects were similar for each indication, except for those unique to the specific organ involved. The type of adverse effects observed in pediatric patients was similar to those seen in adults, with the exception of abdominal pain, anemia, diarrhea, fever, hypertension, infection, pharyngitis, respiratory tract infection, sepsis, and vomiting, which were more frequent in pediatric patients; lymphoproliferative disorder was the only type of malignancy observed.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <i>As reported in adults following oral dosing of CellCept alone in renal, cardiac, and hepatic allograft rejection studies: </i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Chest pain, edema, hypertension, hypotension, peripheral edema, tachycardia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Anxiety, dizziness, headache, insomnia, pain, paresthesia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hypercholesterolemia, hyperglycemia, hyperkalemia, hypocalcemia, hypokalemia, hypomagnesemia, increased lactate dehydrogenase</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Abdominal pain, anorexia, constipation, diarrhea, dyspepsia, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Urinary tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Anemia, hypochromic anemia, leukocytosis, leukopenia, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Abnormal hepatic function tests, ascites</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Candidiasis, herpes simplex infection, infection, sepsis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Back pain, weakness, tremor</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Increased blood urea nitrogen, increased serum creatinine, renal function abnormality</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Cough, dyspnea, pleural effusion, pulmonary disease, respiratory tract infection, sinusitis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <i>Use in combination with cyclosporine and corticosteroids:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Angina pectoris, arterial thrombosis, atrial fibrillation, atrial flutter, bradycardia, cardiac arrhythmia, cardiac failure, extrasystoles, facial edema, increased venous pressure, orthostatic hypotension, palpitations, pericardial effusion, peripheral vascular disorder, supraventricular extrasystole, supraventricular tachycardia, syncope, thrombosis, vasodilatation, vasospasm, ventricular premature contractions, ventricular tachycardia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Abnormality in thinking, agitation, confusion, delirium, depression, drowsiness, emotional lability, hallucination, hypertonia, hypoesthesia, malaise, myasthenia, nervousness, neuropathy, psychosis, seizure, vertigo, voice disorder</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Acne vulgaris, alopecia, cellulitis, dermal ulcer, diaphoresis, fungal dermatitis, pallor, pruritus, skin hypertrophy, vesiculobullous dermatitis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Acidosis, albuminuria, alkalosis, Cushing's syndrome, dehydration, diabetes mellitus, gout, hirsutism, hypercalcemia, hyperphosphatemia,  hyperlipidemia, hypervolemia, hypochloremia, hypoglycemia, hyponatremia, hypophosphatemia, hypoproteinemia, hypothyroidism, hypovolemia, increased gamma-glutamyl transferase, increased thirst, parathyroid disease, weight gain, weight loss</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Cholangitis, dysphagia, enlargement of abdomen, esophagitis, flatulence, gastric disease, gastric ulcer, gastritis, gastroenteritis, gastrointestinal hemorrhage, GI moniliasis, gingival hyperplasia, gingivitis, hernia, hiccups, intestinal obstruction, melena, mucocutaneous candidiasis, oral candidiasis, oral mucosa ulcer, peritonitis, stomatitis, xerostomia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Dysuria, hematuria, impotence, nocturia, oliguria, pelvic pain, prostatic disease, scrotal edema, urinary frequency, urinary incontinence, urinary retention, urinary tract abnormality</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Blood coagulation disorder, bruise, hemophthalmos, hemorrhage, neoplasm, neutropenia, pancytopenia, petechia, polycythemia, prolonged prothrombin time, prolonged partial thromboplastin time, skin carcinoma</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Cholestatic jaundice, hepatic insuffiency, hepatitis, hyperbilirubinemia, increased serum alkaline phosphatase, increased serum transaminases, jaundice</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Abscess (local), cytomegalovirus disease (includes viremia/syndrome and tissue invasive disease), herpes zoster (cutaneous disease), infection (of ileus)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Arthralgia, arthropathy, leg cramps, myalgia, neck pain, osteoporosis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Abnormal lacrimation, amblyopia, cataract, conjunctivitis, visual disturbance</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Otic: Deafness, ear disease, otalgia, tinnitus</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Hydronephrosis, increased serum creatinine, pyelonephritis, renal failure, renal tubular necrosis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Apnea, asthma, atelectasis, bronchitis, epistaxis, flu-like symptoms, hemoptysis, hyperventilation, hypoxia, increased bronchial secretions, pharyngitis, pneumonia, pneumothorax, pulmonary edema, pulmonary hypertension, respiratory acidosis, respiratory tract infection (moniliasis), rhinitis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Abnormal healing, cyst, fever and chills</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Rare but important or life-threatening: Atypical mycobacterial infection, bronchiectasis (Boddana 2011, Rook 2006), colitis, endocarditis (infectious), gastrointestinal perforation, hypogammaglobulinemia (Boddana 2011; Keven 2003; Robertson 2009), interstitial pulmonary disease, lymphoproliferative disorder, malabsorption (intestinal villous atrophy), malignant lymphoma, malignant neoplasm, meningitis, pancreatitis, progressive multifocal leukoencephalopathy, pulmonary fibrosis, pure red cell aplasia, renal disease (BK virus-associated), tuberculosis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F198665\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to mycophenolate mofetil, mycophenolic acid, mycophenolate sodium, or any component of the formulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cellcept: Intravenous formulation is also contraindicated in patients who are allergic to polysorbate 80</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling: </i>Additional contraindications (not in the US labeling): Pregnancy; women of childbearing potential and not using highly effective contraceptive methods; women of childbearing potential not providing a pregnancy test result; breast-feeding</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F198648\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infections: <b>[US Boxed Warning]: Risk for bacterial, viral, fungal, and protozoal infections, including opportunistic infections, is increased with immunosuppressant therapy</b>; infections may be serious and potentially fatal. Due to the risk of oversuppression of the immune system, which may increase susceptibility to infection, combination immunosuppressant therapy should be used with caution.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; New or reactivated viral infections: Polyomavirus associated nephropathy (PVAN), JC virus-associated progressive multifocal leukoencephalopathy (PML), cytomegalovirus (CMV) infections, and reactivation of hepatitis B (HBV) or hepatitis C (HCV) have been reported with use. A reduction in immunosuppression should be considered for patients with new or reactivated viral infections; however, in transplant recipients, the risk that reduced immunosuppression presents to the functioning graft should also be considered. PVAN, primarily from activation of BK virus, may lead to the deterioration of renal function and/or renal graft loss. PML, a potentially fatal condition, commonly presents with apathy, ataxia, cognitive deficiencies, confusion, and hemiparesis. Risk factors for development of PML include treatment with immunosuppressants and immune function impairment; consultation with a neurologist should be considered in any patient with neurological symptoms receiving immunosuppressants. Risk of CMV viremia or disease is increased in transplant recipients CMV seronegative at the time of transplant who receive a graft from a CMV seropositive donor; however, routine approaches to limiting CMV exist and should be utilized. In patients infected with HBV or HCV, viral reactivation may occur; these patients should be monitored for signs of active HBV or HCV.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Lymphoproliferative disorders: <b>[US Boxed Warning]: Risk of development of lymphoma and skin malignancy is increased.</b> The risk for malignancies is related to intensity/duration of therapy. Patients should be monitored appropriately, instructed to limit exposure to sunlight/UV light to decrease the risk of skin cancer, and given supportive treatment should these conditions occur. Post-transplant lymphoproliferative disorder related to EBV infection has been reported in immunosuppressed organ transplant patients; risk is highest in EBV seronegative patients (including many young children).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neutropenia: Neutropenia (including severe neutropenia) may occur, requiring dose reduction or interruption of treatment (risk greater from day 31-180 post-transplant).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pure red cell aplasia (PRCA): PRCA, a type of anemia which can range from subclinical to severe, has been reported in patients receiving mycophenolate concomitantly with other immunosuppressive agents (eg, tacrolimus, cyclosporine, corticosteroids). Symptoms may include fatigue, lethargy, or pallor. Although not precisely known, risk factors for the development of PRCA may include immunosuppression and treatment with immunosuppressant therapy. Dose reduction or discontinuation of immunosuppressive therapy may reverse PRCA; however, in transplant recipients, the risk of reduced immunosuppression and graft rejection should be considered.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastrointestinal disorders: Use may rarely be associated with gastric or duodenal ulcers, GI bleeding and/or perforation. Use caution in patients with active serious digestive system disease; patients with active peptic ulcers were not included in clinical studies.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypoxanthine-guanine phosphoribosyltransferase deficiency: Theoretically, use should be avoided in patients with the rare hereditary deficiency of hypoxanthine-guanine phosphoribosyltransferase (such as Lesch-Nyhan or Kelley-Seegmiller syndrome).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment as toxicity may be increased; may require dosage adjustment in severe impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Concurrent drug therapy issues:</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Non-interchangeability of dosage forms: Mycophenolate sodium and mycophenolate mofetil should <b>not</b> be used interchangeably without health care provider supervision because the rate of absorption following the administration of these two products is not equivalent. Single dose pharmacokinetic studies in adult renal transplant patients suggest that bioavailability is similar between oral mycophenolate mofetil (1,000 mg) and delayed release mycophenolic acid (720 mg) (Arns 2005). In clinical trials, comparative efficacy and safety profiles have been observed in adult renal transplant patients randomized to either oral mycophenolate mofetil (1,000 mg twice daily) or delayed release mycophenolic acid (720 mg twice daily) (Budde, 2004; 2003).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Phenylalanine: Some dosage forms may contain phenylalanine.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson, 2002; Lucente 2000; Shelley, 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade, 1986; CDC, 1984). See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pregnancy: <b>[US Boxed Warning]: Mycophenolate is associated with an increased risk of congenital malformations and first trimester pregnancy loss when used by pregnant women. Females of reproductive potential must be counseled about pregnancy prevention and planning.</b> Alternative agents should be considered for women planning a pregnancy. Females of reproductive potential should have a negative pregnancy test with a sensitivity of &ge;25 milliunits/mL immediately before therapy and the test should be repeated 8-10 days later. Pregnancy tests should be repeated during routine follow-up visits. Acceptable forms of contraception should be used during treatment and for 6 weeks after therapy is discontinued.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Experienced physician: <b>[US Boxed Warning]: Should be administered under the supervision of a physician experienced in immunosuppressive therapy. </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Immunizations: Live attenuated vaccines should be avoided during use; vaccinations may be less effective during therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; IV administration: Intravenous solutions should be given over at least 2 hours; <b>never</b> administer intravenous solution by rapid or bolus injection.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299731\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of OAT3, OATP1B1/SLCO1B1, OATP1B3/SLCO1B3, UGT1A10, UGT1A8, UGT1A9, UGT2B7</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F198653\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12624&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Acyclovir-Valacyclovir: May increase the serum concentration of Mycophenolate. Mycophenolate may increase the serum concentration of Acyclovir-Valacyclovir.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antacids: May decrease the absorption of Mycophenolate. Management: Separate doses of mycophenolate and antacids by at least 2 hours. Monitor for reduced effects of mycophenolate if taken concomitant with antacids.<b> Exceptions: </b>Sodium Bicarbonate.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bile Acid Sequestrants: May decrease the serum concentration of Mycophenolate.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholestyramine Resin: May decrease the serum concentration of Mycophenolate.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): May decrease the serum concentration of Mycophenolate. Specifically, cyclosporine may decrease concentrations of the active metabolite mycophenolic acid. Management: Mycophenolate requirements may be greater in patients receiving cyclosporine. Monitor mycophenolate dosing and response to therapy particularly closely when adjusting concurrent cyclosporine (starting, stopping, or changing dose).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estrogen Derivatives (Contraceptive): Mycophenolate may decrease the serum concentration of Estrogen Derivatives (Contraceptive). Average AUC values were unchanged, but there was evidence of substantial patient-to-patient variability in response to this combination.  Management: Women of childbearing potential who are receiving mycophenolate mofetil should consider using an alternative and/or additional form of contraception.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ganciclovir-Valganciclovir: Mycophenolate may increase the serum concentration of Ganciclovir-Valganciclovir. Ganciclovir-Valganciclovir may increase the serum concentration of Mycophenolate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Isavuconazonium Sulfate: May increase the serum concentration of Mycophenolate.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium Salts: May decrease the serum concentration of Mycophenolate. Management: Separate doses of mycophenolate and oral magnesium salts. Monitor for reduced effects of mycophenolate if taken concomitant with oral magnesium salts.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetroNIDAZOLE (Systemic): May decrease the serum concentration of Mycophenolate. Specifically, metronidazole may decrease concentrations of the active metabolite of mycophenolate.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Penicillins: May decrease serum concentrations of the active metabolite(s) of Mycophenolate. This effect appears to be the result of impaired enterohepatic recirculation.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probenecid: May increase the serum concentration of Mycophenolate.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Progestins (Contraceptive): Mycophenolate may decrease the serum concentration of Progestins (Contraceptive).  Management: Use of an additional or alternative (nonhormonal) method of contraception should be considered.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Proton Pump Inhibitors: May decrease the serum concentration of Mycophenolate. Specifically, concentrations of the active mycophenolic acid may be reduced.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinolones: May decrease the serum concentration of Mycophenolate. Specifically, quinolones may decrease concentrations of the active metabolite of mycophenolate.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rifamycin Derivatives: May decrease the serum concentration of Mycophenolate. Specifically, rifamycin derivatives may decrease the concentration of the active metabolite mycophenolic acid.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sevelamer: May decrease the serum concentration of Mycophenolate. Management: Administer mycophenolate at least 2 hours prior to sevelamer administration.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Teriflunomide: May increase the serum concentration of OAT3 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or nonbiologic disease modifying antirheumatic drugs (DMARDs) is permitted, and this warning seems particularly focused on more potent immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F198682\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Food decreases C<sub>max</sub> of MPA by 40% following CellCept administration and 33% following Myfortic use; the extent of absorption is not changed. Management: Take CellCept or Myfortic on an empty stomach to decrease variability; however, Cellcept may be taken with food if necessary in stable renal transplant patients.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F198655\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">D (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F198668\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>[US Boxed Warning]: Mycophenolate is associated with an increased risk of congenital malformations and first trimester pregnancy loss when used by pregnant women. Females of reproductive potential must be counseled about pregnancy prevention and planning.</b> Alternative agents with less potential for embryofetal toxicity should be considered for women planning a pregnancy. The following congenital malformations have been reported following exposure during pregnancy: External ear abnormalities, cleft lip and palate, anomalies of the distal limbs, heart, esophagus, kidney, and nervous system. The combination of ear, eye, and lip/palate abnormalities has been identified as mycophenolate embryopathy (Perez-Aytes 2017). Spontaneous abortions have also been noted.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Females of reproductive potential (girls who have entered puberty and women with a uterus who have not passed through clinically confirmed menopause) should have a negative pregnancy test with a sensitivity of &ge;25 milliunits/mL immediately before mycophenolate therapy and the test should be repeated 8 to 10 days later. Pregnancy tests should then be repeated during routine follow-up visits. Acceptable forms of contraception should be used during treatment and for 6 weeks after therapy is discontinued. The effectiveness of hormonal contraceptive agents may be affected by mycophenolate.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Current guidelines recommend that pregnancy be delayed following a kidney transplant until 1 year has passed without an acute rejection; this time period may be adjusted as clinically appropriate. Women planning a pregnancy and who are already taking mycophenolate following a kidney transplant should be switched to a different medication and mycophenolate should be discontinued for at least 6 weeks before pregnancy is attempted (KDIGO 2009). Mycophenolate is not recommended for the treatment of psoriasis in pregnant women (Menter 2009). Mycophenolate should not be used during pregnancy in women with lupus nephritis; women who become pregnant during mycophenolate therapy should be switched to a different medication (KDIGO 2012). For women with lupus nephritis taking mycophenolate and who are planning a pregnancy, mycophenolate should be discontinued at least 6 weeks prior to trying to conceive (Hahn 2012).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Health care providers should report female exposures to mycophenolate during pregnancy or within 6 weeks of discontinuing therapy to the Mycophenolate Pregnancy Registry (800-617-8191).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The National Transplantation Pregnancy Registry (NTPR) is a registry which follows pregnancies which occur in maternal transplant recipients or those fathered by male transplant recipients. The NTPR encourages reporting of pregnancies following solid organ transplant by contacting them at 877-955-6877 or NTPR@giftoflifeinstitute.org.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1048785\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Complete blood count (weekly for first month, twice monthly during months 2 and 3, then monthly thereafter through the first year); renal and liver function; signs and symptoms of organ rejection; signs and symptoms of bacterial, fungal, protozoal, new or reactivated viral, or opportunistic infections; neurological symptoms (eg, hemiparesis, confusion, cognitive deficiencies, ataxia) suggestive of PML, pregnancy test (immediately prior to initiation and 8-10 days later in females of childbearing potential, followed by repeat tests during therapy); monitor skin (for lesions suspicious of skin cancer); monitor for signs of lymphoma</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F198647\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">MPA exhibits a cytostatic effect on T and B lymphocytes. It is an inhibitor of inosine monophosphate dehydrogenase (IMPDH) which inhibits <i>de novo</i> guanosine nucleotide synthesis. T and B lymphocytes are dependent on this pathway for proliferation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F198664\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Peak effect: Correlation of toxicity or efficacy is still being developed, however, one study indicated that 12-hour AUCs &gt;40 mcg/mL/hour were correlated with efficacy and decreased episodes of rejection </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Rapid and extensive; early post-transplant period mycophenolic acid (MPA) AUC values are lower (~45% to 53%) than later post-transplant period (&gt;3 months) MPA AUC values in both pediatric patients and adults</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Oral: Myfortic: 93%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CellCept: MPA: Oral: 4 L/kg; IV: 3.6 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Myfortic: MPA: Oral: 54 L (at steady state); 112 L (elimination phase)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: MPA: &gt;97%, MPAG 82% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic and via GI tract; CellCept is completely hydrolyzed in the liver to mycophenolic acid (MPA; active metabolite); enterohepatic recirculation of MPA may occur; MPA is glucuronidated to MPAG (inactive metabolite) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: Oral: CellCept: 80.7% to 94%; enterohepatic recirculation contributes to MPA concentration (Staatz 2007); two 500 mg tablets have been shown to be bioequivalent to four 250 mg capsules or 1,000 mg of oral suspension; Myfortic: 72% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CellCept: MPA: Oral: 18 hours; IV: 17 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Myfortic: MPA: Oral: 8 to 16 hours; MPAG: 13 to 17 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, plasma: Oral: MPA:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CellCept: 1 to 1.5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Myfortic: 1.5 to 2.75 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CellCept: MPA: Urine (&lt;1%), feces (6%); MPAG: Urine (87%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Myfortic: MPA: Urine (3%), feces; MPAG: Urine (&gt;60%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10073346\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:0em;display:inline\">A direct conversion factor from mycophenolate mofetil to mycophenolic acid (delayed release) is not available. In one study, adults on mycophenolate mofetil 1000 mg twice daily were successfully converted to mycophenolic acid (delayed release) 720 mg twice daily. In the same study, children (n=17) were converted from 440 &plusmn; 147 mg/m<sup>2</sup> twice daily to mycophenolic acid (delayed release) 432 &plusmn; 51 mg/m<sup>2</sup> twice daily (Massari, 2005).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10893685\" class=\"block exp drugH1Div\"><span class=\"drugH1\">Extemporaneous Preparations</span>\n    <p style=\"text-indent:0em;\">A 50 mg/mL oral suspension may be made with mycophenolate mofetil capsules, Ora-Plus, and cherry syrup. In a vertical flow hood, empty six 250 mg capsules into a mortar; add 7.5 mL Ora-Plus and mix to a uniform paste. Mix while adding 15 mL of cherry syrup in incremental proportions; transfer to a calibrated bottle, rinse mortar with cherry syrup, and add sufficient quantity of cherry syrup to make 30 mL. Label &quot;shake well&quot;. Stable for 210 days at 5&deg;C, for 28 days at 25&deg;C to 37&deg;C, and for 11 days at 45&deg;C.</p>\n    <div class=\"reference\">Venkataramanan R, McCombs JR, Zuckerman S, et al, &quot;Stability of Mycophenolate Mofetil as an Extemporaneous Suspension,&quot; <i>Ann Pharmacother</i>, 1998, 32(7-8):755-7.<span class=\"pubmed-id\">9681090</span></div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F198667\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (CellCept Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (100): $1,079.51</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Mycophenolate Mofetil Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (100): $396.29</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (CellCept Intravenous Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (1): $129.57</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Mycophenolate Mofetil HCl Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (1): $116.62</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension (reconstituted)</b> (CellCept Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg/mL (160 mL): $1,657.04</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension (reconstituted)</b> (Mycophenolate Mofetil Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg/mL (160 mL): $1,367.45</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, EC</b> (Mycophenolate Sodium Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">180 mg (120): $548.26</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">360 mg (120): $1,096.50</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, EC</b> (Myfortic Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">180 mg (120): $749.30</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">360 mg (120): $1,498.62</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (CellCept Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (100): $2,159.02</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Mycophenolate Mofetil Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (100): $792.59</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F198671\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Accocept (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Atajec (PH);</li>\n      <li>Celguard (BD);</li>\n      <li>Cellcept (AE, AT, BH, CL, CN, CU, CY, CZ, DK, ES, HR, HU, IS, JO, JP, KW, LB, LK, LT, LV, NO, PL, QA, RO, SA, VN);</li>\n      <li>CellCept (BB, BF, BJ, BM, BS, BZ, CI, ET, GH, GM, GN, GY, HK, IE, JM, KE, LR, MA, ML, MR, MT, MU, MW, NE, NG, NZ, PY, SC, SD, SI, SK, SL, SN, SR, TN, TR, TT, TZ, UG, ZA, ZM, ZW);</li>\n      <li>Cellmune (IN);</li>\n      <li>Ceptolate (AU);</li>\n      <li>Graftcept (BD);</li>\n      <li>Imulate (AU, NZ);</li>\n      <li>Linfonex (CL, EC, PY);</li>\n      <li>Micocept (HK);</li>\n      <li>Micoflavin (EC);</li>\n      <li>Mofilet (LK);</li>\n      <li>Mowel (AT);</li>\n      <li>Myclausen (IE);</li>\n      <li>Mycofit (ET);</li>\n      <li>Mycokem (PH);</li>\n      <li>Mycolat (IE);</li>\n      <li>Mycopen (PH);</li>\n      <li>Mycotil (BD);</li>\n      <li>Myfenax (ES, IE, LK, MT, PL);</li>\n      <li>Myfortic (AE, AR, AT, AU, BB, BE, BG, BH, BR, CH, CL, CN, CO, CU, CY, CZ, DE, DK, EC, EE, ES, FI, FR, GB, GR, HN, HR, ID, IE, IL, IS, IT, JO, KR, KW, LB, LK, LT, LV, MT, MX, MY, NL, NO, PE, PH, PK, PL, PT, PY, QA, RO, RU, SA, SE, SG, SI, SK, TH, TR, TW, UY, VE, VN);</li>\n      <li>Myotec (PH);</li>\n      <li>Nuodun (CN);</li>\n      <li>Phenocept (BD);</li>\n      <li>Suprimun (CL);</li>\n      <li>Transfonex (VN);</li>\n      <li>Unorem (PH)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Alade SL, Brown RE, Paquet A. Polysorbate 80 and E-Ferol toxicity. Pediatrics. 1986;77(4):593-597. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-enteric-coated-mycophenolate-sodium-myfortic-pediatric-drug-information/abstract-text/3960626/pubmed\" target=\"_blank\" id=\"3960626\">3960626</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Appel GB, Contreras G, Dooley MA, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. <i>J Am Soc Nephrol</i>. 2009;20(5):1103-1112.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-enteric-coated-mycophenolate-sodium-myfortic-pediatric-drug-information/abstract-text/19369404/pubmed\" target=\"_blank\" id=\"19369404\">19369404</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aragon E, Chan YH, Ng KH, et al. Good outcomes with mycophenolate-cyclosporine-based induction protocol in children with severe proliferative lupus nephritis. <i>Lupus</i>. 2010;19(8):965-973.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-enteric-coated-mycophenolate-sodium-myfortic-pediatric-drug-information/abstract-text/20581019/pubmed\" target=\"_blank\" id=\"20581019\">20581019</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>. 5th ed. Philadelphia, PA: American College of Physicians; 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baskin E, Ozen S, Cakar N, et al. The use of low-dose cyclophosphamide followed by AZA/MMF treatment in childhood lupus nephritis. <i>Pediatr Nephrol</i>. 2010;25(1):111-117.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-enteric-coated-mycophenolate-sodium-myfortic-pediatric-drug-information/abstract-text/19727839/pubmed\" target=\"_blank\" id=\"19727839\">19727839</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Beck L, Bomback AS, Choi MJ, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis. <i>Am J Kidney Dis</i>. 2013;62(3):403-441. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-enteric-coated-mycophenolate-sodium-myfortic-pediatric-drug-information/abstract-text/23871408/pubmed\" target=\"_blank\" id=\"23871408\">23871408</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    CellCept (mycophenolate) [prescribing information]. South San Francisco, CA: Genentech USA, Inc; September 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. MMWR Morb Mortal Wkly Rep. 1984;33(14):198-199 <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-enteric-coated-mycophenolate-sodium-myfortic-pediatric-drug-information/abstract-text/6423951/pubmed\" target=\"_blank\" id=\"6423951\">6423951</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Contreras G, Pardo V, Leclercq B, et al. Sequential therapies for proliferative lupus nephritis. <i>N Engl J Med</i>. 2004;350(10):971-980.  <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-enteric-coated-mycophenolate-sodium-myfortic-pediatric-drug-information/abstract-text/14999109/pubmed\" target=\"_blank\" id=\"14999109\">14999109</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cramer CH 2nd, Mills M, Valentini RP, et al. Clinical presentation and outcome in a cohort of paediatric patients with membranous lupus nephritis. <i>Nephrol Dial Transplant</i>. 2007;22(12):3495-3500.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-enteric-coated-mycophenolate-sodium-myfortic-pediatric-drug-information/abstract-text/17664180/pubmed\" target=\"_blank\" id=\"17664180\">17664180</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dooley MA, Jayne D, Ginzler EM, et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. <i>N Engl J Med</i>. 2011;365(20):1886-1895.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-enteric-coated-mycophenolate-sodium-myfortic-pediatric-drug-information/abstract-text/22087680/pubmed\" target=\"_blank\" id=\"22087680\">22087680</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ettenger R, Warshaw B, Menster M, et al, &ldquo;Mycophenolate Mofetil in Pediatric Renal Transplantation: A Report of the Ped MMF Study Group.&rdquo; Abstract: 1996, Annual Meeting, ASTP. </div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Falcini F, Capannini S, Martini G, et al. Mycophenolate mofetil for the treatment of juvenile onset SLE: a multicenter study. <i>Lupus</i>. 2009;18(2):139-143.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-enteric-coated-mycophenolate-sodium-myfortic-pediatric-drug-information/abstract-text/19151115/pubmed\" target=\"_blank\" id=\"19151115\">19151115</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gipson DS, Massengill SF, Yao L, et al, &quot;Management of Childhood Onset Nephrotic Syndrome,&quot; <i>Pediatrics</i>, 2009, 124(2):747-57.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-enteric-coated-mycophenolate-sodium-myfortic-pediatric-drug-information/abstract-text/19651590/pubmed\" target=\"_blank\" id=\"19651590\">19651590</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hahn BH, McMahon MA, Wilkinson A, et al, &quot;American College of Rheumatology Guidelines for Screening, Treatment, and Management of Lupus Nephritis,&quot; <i>Arthritis Care Res (Hoboken)</i>, 2012, 64(6):797-808.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-enteric-coated-mycophenolate-sodium-myfortic-pediatric-drug-information/abstract-text/22556106/pubmed\" target=\"_blank\" id=\"22556106\">22556106</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hobbs DJ, Barletta GM, Rajpal JS, et al. Severe paediatric systemic lupus erythematosus nephritis-a single-centre experience. <i>Nephrol Dial Transplant</i>. 2010;25(2):457-463.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-enteric-coated-mycophenolate-sodium-myfortic-pediatric-drug-information/abstract-text/19755473/pubmed\" target=\"_blank\" id=\"19755473\">19755473</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hogg RJ, Fitzgibbons L, Bruick J, et al, &quot;Mycophenolate Mofetil in Children With Frequently Relapsing Nephrotic Syndrome: A Report From the Southwest Pediatric Nephrology Study Group,&quot; <i>Clin J Am Soc Nephrol</i>, 2006, 1(6):1173-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-enteric-coated-mycophenolate-sodium-myfortic-pediatric-drug-information/abstract-text/17699344/pubmed\" target=\"_blank\" id=\"17699344\">17699344</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n     Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. Contact Dermatitis. 2002;47:313.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kazyra I, Pilkington C, Marks SD, et al. Mycophenolate mofetil treatment in children and adolescents with lupus. <i>Arch Dis Child</i>. 2010;95(12):1059-1061.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-enteric-coated-mycophenolate-sodium-myfortic-pediatric-drug-information/abstract-text/20810399/pubmed\" target=\"_blank\" id=\"20810399\">20810399</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kidney disease: improving global outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO clinical practice guideline for glomerulonephritis. <i>Kidney Inter</i>. 2012;2:139&ndash;274.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kobashigawa JA, Renlund DG, Gerosa G, et al, &quot;Similar Efficacy and Safety of Enteric-Coated Mycophenolate Sodium (EC-MPS, Myfortic) Compared With Mycophenolate Mofetil (MMF) in <i>de novo</i> Heart Transplant Recipients: Results of a 12-Month, Single-Blind, Randomized, Parallel-Group, Multicenter Study,&quot; <i>J Heart Lung Transplant</i>, 2006, 25(8):935-41.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-enteric-coated-mycophenolate-sodium-myfortic-pediatric-drug-information/abstract-text/16890114 /pubmed\" target=\"_blank\" id=\"16890114 \">16890114 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. Contact Dermatitis. 2000;43:172.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Marks SD, Tullus K. Modern therapeutic strategies for paediatric systemic lupus erythematosus and lupus nephritis. <i>Acta Paediatr</i>. 2010;99(7):967-974.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-enteric-coated-mycophenolate-sodium-myfortic-pediatric-drug-information/abstract-text/20222881/pubmed\" target=\"_blank\" id=\"20222881\">20222881</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Massari P, Duro-Garcia V, Gir&oacute;n F, et al, &quot;Safety Assessment of the Conversion From Mycophenolate Mofetil to Enteric-Coated Mycophenolate Sodium in Stable Renal Transplant Recipients,&quot; <i>Transplant Proc</i>, 2005, 37(2):916-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-enteric-coated-mycophenolate-sodium-myfortic-pediatric-drug-information/abstract-text/15848574/pubmed\" target=\"_blank\" id=\"15848574\">15848574</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Myfortic (mycophenolate) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; September 2013. </div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ong LM, Hooi LS, Lim TO, et al. Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis. <i>Nephrology (Carlton)</i>. 2005;10(5):504-510.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-enteric-coated-mycophenolate-sodium-myfortic-pediatric-drug-information/abstract-text/16221103/pubmed\" target=\"_blank\" id=\"16221103\">16221103</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. Lancet. 1995;345(8980):1312-1313.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sollinger HW, &ldquo;Mycophenolate Mofetil for the Prevention of Acute Rejection in Primary Cadaveric Renal Allograft Recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group,&rdquo; <i>Transplantation</i>, 1995, 60:225-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-enteric-coated-mycophenolate-sodium-myfortic-pediatric-drug-information/abstract-text/7645033/pubmed\" target=\"_blank\" id=\"7645033\">7645033</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Staatz CE and Tett SE, &quot;Clinical Pharmacokinetics and Pharmacodynamics of Mycophenolate in Solid Organ Transplant Recipients,&quot; <i>Clin Pharmacokinet</i>, 2007, 46(1):13-58.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-enteric-coated-mycophenolate-sodium-myfortic-pediatric-drug-information/abstract-text/17201457/pubmed\" target=\"_blank\" id=\"17201457\">17201457</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wong SN, Chan WK, Hui J, et al. Membranous lupus nephritis in Chinese children--a case series and review of the literature. <i>Pediatr Nephrol</i>. 2009 Oct;24(10):1989-1996. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mycophenolate-mofetil-cellcept-and-enteric-coated-mycophenolate-sodium-myfortic-pediatric-drug-information/abstract-text/19626343/pubmed\" target=\"_blank\" id=\"19626343\">19626343</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12624 Version 212.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5709159\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F198686\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F198687\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1048786\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1048778\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F198659\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F198644\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F7874743\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1048789\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49132818\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F198680\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1048788\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F25708052\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F198716\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F198665\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F198648\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299731\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F198653\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F198682\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F198655\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F198668\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1048785\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F198647\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F198664\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F10073346\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Extemporaneous Preparations\" href=\"#F10893685\" class=\"outlineLink\">Extemporaneous Preparations</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F198667\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F198671\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12624|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=mycophenolate-mofetil-cellcept-and-enteric-coated-mycophenolate-sodium-myfortic-drug-information\" class=\"drug drug_general\">Mycophenolate mofetil (Cellcept) and enteric-coated mycophenolate sodium (Myfortic): Drug information</a></li><li><a href=\"topic.htm?path=mycophenolate-mofetil-cellcept-and-enteric-coated-mycophenolate-sodium-myfortic-patient-drug-information\" class=\"drug drug_patient\">Mycophenolate mofetil (Cellcept) and enteric-coated mycophenolate sodium (Myfortic): Patient drug information</a></li></ul></div></div>","javascript":null}